Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
Open Access
- 1 March 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (3) , eaav5010
Abstract
Dual complementary liposomes inhibit proliferation and metastasis in triple-negative breast cancer.Keywords
Funding Information
- National Cancer Institute (1DP2CA174495)
- National Cancer Institute (R01CA185530)
- Breast Cancer Research Foundation
This publication has 56 references indexed in Scilit:
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METNature Medicine, 2012
- Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacyInternational Journal of Nanomedicine, 2011
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Exosomes: Extracellular organelles important in intercellular communicationJournal of Proteomics, 2010
- Immunoliposomes That Target Endothelium In Vitro Are Dependent on Lipid Raft FormationMolecular Pharmaceutics, 2010
- Mouse models for breast cancer metastasisBiochemical and Biophysical Research Communications, 2010
- Lipocalin 2 promotes breast cancer progressionProceedings of the National Academy of Sciences, 2009
- Single-step surface functionalization of polymeric nanoparticles for targeted drug deliveryBiomaterials, 2009
- The effect of particle design on cellular internalization pathwaysProceedings of the National Academy of Sciences, 2008
- Control of EGF Receptor Signaling by Clathrin-Mediated EndocytosisScience, 1996